FDAnews
www.fdanews.com/articles/196510-emergent-biosolutions-partners-with-hhs-for-plasma-derived-covid-19-treatment
COVID-19 Treatment

Emergent BioSolutions Partners with HHS for Plasma-Derived COVID-19 Treatment

April 3, 2020

Emergent BioSolutions is developing a plasma-derived treatment for COVID-19 with the help of $14.5 million in funding from HHS’ Biomedical Advanced Research and Development Authority.

COVID-HIG is being developed as a possible treatment for hospitalized patients with severe symptoms and high-risk, acute symptomatic patients to prevent progression to severe symptoms. The drug will use antibodies from the plasma of patients who have recovered from the disease.

The National Institutes of Health has agreed to incorporate COVID-HIG into one of its clinical trials once clinical material becomes available.

View today's stories